Followers | 2540 |
Posts | 250759 |
Boards Moderated | 35 |
Alias Born | 05/06/2014 |
Thursday, June 08, 2017 8:25:08 AM
Source: PR Newswire (US)
CAMBRIDGE, Mass., June 8, 2017 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced the expansion of its senior management team through the addition of two new executive hires. Sergio L. Santillana, M.D., MSc, a medical oncologist with extensive industry experience leading a wide range of clinical development programs, has been appointed to the role of Chief Medical Officer, effective June 12, 2017. In addition, Ellen K. Forest, who served most recently as Director of Human Resources at Baxalta, has joined Merrimack to lead its talent and recruitment strategy as the new Head of Human Resources.
Merrimack Pharmaceuticals Logo (PRNewsFoto/Merrimack Pharmaceuticals, Inc.)
"We are pleased to welcome Sergio and Ellen to Merrimack to help lead our organization in the execution of our refocused research and clinical development strategy," said Richard Peters, M.D., Ph.D., President and Chief Executive Officer. "The collective expertise of our expanded management team is an invaluable asset to Merrimack as we focus on pinpoint execution across three wholly-owned, innovative and promising clinical-stage programs. With funding into the second half of 2019 to support our corporate objectives, a refined strategic focus and experienced teams in place to execute, we are poised to deliver on the long-term potential of our pipeline for cancer patients and our shareholders."
Sergio L. Santillana, M.D., MSc, previously served as Chief Medical Officer at ARIAD Pharmaceuticals, a commercial-stage biotechnology company acquired by Takeda Pharmaceuticals earlier this year. Prior to joining ARIAD, Dr. Santillana served in various oncology clinical development leadership roles at Takeda, GlaxoSmithKline and Eli Lilly. Before entering the biopharma industry, Dr. Santillana was a practicing board-certified medical oncologist for 15 years, including tenure at the National Cancer Institute of Peru (INEN). Dr. Santillana holds an M.S. in Experimental Therapeutics from Kellogg College at the University of Oxford and an M.D. and B.S. from the Universidad Nacional Federico Villarreal School of Medicine.
Ellen K. Forest served as Director of Human Resources at Baxalta, a global biopharmaceutical company and spin-off of Baxter International, until the company was acquired by Shire in 2016. Previously, Ms. Forest held leadership positions in Human Resources at Partners HealthCare System, the hospital system affiliated with Harvard Medical School; Dovetail Health, a home healthcare company; and TA Associates, a global private equity firm. Ms. Forest holds an M.S. in Human Resources Management and a B.S. from Emmanuel College.
About Merrimack
Merrimack is a biopharmaceutical company based in Cambridge, Massachusetts that is outthinking cancer to ensure that patients and their families live fulfilling lives. Its mission is to transform cancer care through the smart design and development of targeted solutions based on the deep understanding of cancer pathways and biological markers. All of Merrimack's product candidates, including three in clinical studies and several others in preclinical development, fit into its strategy of 1) understanding the biological problems it is trying to solve, 2) designing specific solutions and 3) developing those solutions for biomarker-selected patients. This three-pronged strategy seeks to ensure optimal patient outcomes. For more information, please visit Merrimack's website at www.merrimack.com.
Forward Looking Statements
Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.
Contact:
Geoffrey Grande, CFA
617-441-7602
ggrande@merrimack.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/merrimack-announces-expansion-of-senior-management-team-with-appointment-of-sergio-santillana-as-chief-medical-officer-and-ellen-forest-as-head-of-human-resources-300470648.html
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright 2017 PR Newswire
Recent MACK News
- Form 15-12G - Securities registration termination [Section 12(g)] • Edgar (US Regulatory) • 05/20/2024 08:05:28 PM
- Form 25 - Notification of the removal from listing and registration of matured, redeemed or retired securities • Edgar (US Regulatory) • 05/10/2024 08:45:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/10/2024 08:43:01 PM
- Merrimack Pharmaceuticals, Inc. Announces Stockholder Approval of Plan of Dissolution And Cash Liquidating Dividend Amount of $15.10 Per Share of Common Stock • Business Wire • 05/10/2024 08:30:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/09/2024 11:45:25 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 11:43:00 AM
- Merrimack Pharmaceuticals, Inc. Announces Anticipated Final Cash Dividend Amount of Initial Liquidating Distribution, Subject to Receipt of Stockholder Approval of Plan of Dissolution • Business Wire • 05/09/2024 11:30:00 AM
- Merrimack Pharmaceuticals Announces Notification of Plan to Voluntary Delist Common Stock on NASDAQ Subject to Receipt of Stockholder Approval of Plan of Dissolution • Business Wire • 04/30/2024 09:15:00 PM
- Merrimack Receives $225 Million Milestone Payment from Ipsen • Business Wire • 03/27/2024 08:30:00 PM
- Form 425 - Prospectuses and communications, business combinations • Edgar (US Regulatory) • 03/07/2024 09:42:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:39:03 PM
- Merrimack Reports Full Year 2023 Financial Results • Business Wire • 03/07/2024 09:30:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/07/2024 09:15:29 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 03/07/2024 05:29:51 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/05/2024 09:44:02 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:20:24 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 02/13/2024 09:26:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/13/2024 09:22:56 PM
- Merrimack Reports Ipsen Announcement of Approval By The US FDA of Onivyde® (Irinotecan Liposome Injection) Plus 5 Fluorouracil/Leucovorin and Oxaliplatin (NALIRIFOX) as a First-Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) • Business Wire • 02/13/2024 09:18:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/25/2024 09:05:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/28/2023 09:05:12 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 12/13/2023 09:05:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/11/2023 09:05:08 PM
FEATURED Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM
North Bay Resources Announces Mt. Vernon Gold Mine Bulk Sample, Sierra County, California • NBRI • Sep 11, 2024 9:15 AM
One World Products Issues Shareholder Update Letter • OWPC • Sep 11, 2024 7:27 AM
Kona Gold Beverage Inc. Reports $1.225 Million in Revenue and $133,000 Net Profit for the Quarter • KGKG • Sep 10, 2024 1:30 PM